Literature DB >> 20368505

Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension.

D Walter Wray1, Mark A Supiano.   

Abstract

Aldosterone receptor blockade and thiazide therapy effectively lower blood pressure in geriatric hypertension. Their impact on sympathetic nervous system function has not been evaluated. In a double-blind, randomized study, 36 patients with stage 1 hypertension underwent 6 months of therapy with either aldosterone receptor blockade (spironolactone, n=19; 68+/-1 years) or hydrochlorothiazide (n=17; 68+/-2 years). Arterial blood pressure, [(3)H]-norepinephrine (NE) kinetics (extravascular NE release rate), and alpha-adrenergic responsiveness (forearm vasoconstriction to graded intrabrachial artery NE infusions) were evaluated at baseline, after a 4-week antihypertensive medication withdrawal, and after spironolactone or hydrochlorothiazide treatment. Arterial blood pressure decreased significantly with both spironolactone (160+/-3 to 134+/-2 mm Hg; 77+/-2 to 68+/-2 mm Hg) and hydrochlorothiazide (161+/-4 to 145+/-4 mm Hg; 78+/-2 to 73+/-2 mm Hg) treatment. Sympathetic nervous system activity was significantly reduced after spironolactone (plasma NE: 378+/-40 to 335+/-20 pg/mL, P=0.04; [(3)H]-NE release rate: 2.74+/-0.3 to 1.97+/-0.2 microg/min per meter squared, P=0.04) but not hydrochlorothiazide (plasma NE: 368+/-25 to 349+/-23 pg/mL, P=0.47; [(3)H]-NE release rate: 2.63+/-0.4 to 2.11+/-0.2 mg/min per meter squared, P=0.21). alpha-Adrenergic responsiveness was unchanged with either drug treatment. These findings demonstrate a beneficial effect of aldosterone receptor blockade on reducing sympathetic nervous system activity and blood pressure in hypertensive older patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20368505      PMCID: PMC4989914          DOI: 10.1161/HYPERTENSIONAHA.109.147058

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  42 in total

1.  Sympathetic nervous system activity and alpha-adrenergic responsiveness in older hypertensive humans.

Authors:  M A Supiano; R V Hogikyan; M A Sidani; A T Galecki; J L Krueger
Journal:  Am J Physiol       Date:  1999-03

2.  Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy.

Authors:  A Sato; T Saruta
Journal:  J Int Med Res       Date:  2001 Jan-Feb       Impact factor: 1.671

Review 3.  The incidence and implications of aldosterone breakthrough.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Nat Clin Pract Nephrol       Date:  2007-09

4.  Age-associated arterial wall thickening is related to elevations in sympathetic activity in healthy humans.

Authors:  F A Dinenno; P P Jones; D R Seals; H Tanaka
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-04       Impact factor: 4.733

5.  Human muscle nerve sympathetic activity at rest. Relationship to blood pressure and age.

Authors:  G Sundlöf; B G Wallin
Journal:  J Physiol       Date:  1978-01       Impact factor: 5.182

6.  Diuretic therapy for hypertension and the risk of primary cardiac arrest.

Authors:  D S Siscovick; T E Raghunathan; B M Psaty; T D Koepsell; K G Wicklund; X Lin; L Cobb; P M Rautaharju; M K Copass; E H Wagner
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Arterial alpha-adrenergic responsiveness is decreased and SNS activity is increased in older humans.

Authors:  R V Hogikyan; M A Supiano
Journal:  Am J Physiol       Date:  1994-05

9.  Aldosterone blunts the baroreflex response in man.

Authors:  K M Yee; A D Struthers
Journal:  Clin Sci (Lond)       Date:  1998-12       Impact factor: 6.124

10.  Hydrochlorothiazide and spironolactone in hypertension.

Authors:  G Schrijver; M H Weinberger
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

View more
  13 in total

Review 1.  Modulation of Sympathetic Overactivity to Treat Resistant Hypertension.

Authors:  Raven Voora; Alan L Hinderliter
Journal:  Curr Hypertens Rep       Date:  2018-09-07       Impact factor: 5.369

2.  Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.

Authors:  David E Kandzari; Deepak L Bhatt; Sandeep Brar; Chandan M Devireddy; Murray Esler; Martin Fahy; John M Flack; Barry T Katzen; Janice Lea; David P Lee; Martin B Leon; Adrian Ma; Joseph Massaro; Laura Mauri; Suzanne Oparil; William W O'Neill; Manesh R Patel; Krishna Rocha-Singh; Paul A Sobotka; Laura Svetkey; Raymond R Townsend; George L Bakris
Journal:  Eur Heart J       Date:  2014-11-16       Impact factor: 29.983

3.  Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism.

Authors:  Andrew C Kontak; Zhongyun Wang; Debbie Arbique; Beverley Adams-Huet; Richard J Auchus; Shawna D Nesbitt; Ronald G Victor; Wanpen Vongpatanasin
Journal:  J Clin Endocrinol Metab       Date:  2010-07-21       Impact factor: 5.958

Review 4.  The renin-angiotensin system and cardiovascular autonomic control in aging.

Authors:  Amanda J Miller; Amy C Arnold
Journal:  Peptides       Date:  2021-12-29       Impact factor: 3.750

Review 5.  Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation.

Authors:  Kathleen V Barrett; Amy T McCurley; Iris Z Jaffe
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-12       Impact factor: 2.557

6.  Chronic renin inhibition lowers blood pressure and reduces upright muscle sympathetic nerve activity in hypertensive seniors.

Authors:  Yoshiyuki Okada; Sara S Jarvis; Stuart A Best; Tiffany B Bivens; Beverley Adams-Huet; Benjamin D Levine; Qi Fu
Journal:  J Physiol       Date:  2013-09-23       Impact factor: 5.182

7.  Pathophysiology of resistant hypertension: the role of sympathetic nervous system.

Authors:  Costas Tsioufis; Athanasios Kordalis; Dimitris Flessas; Ioannis Anastasopoulos; Dimitris Tsiachris; Vasilios Papademetriou; Christodoulos Stefanadis
Journal:  Int J Hypertens       Date:  2011-01-20       Impact factor: 2.420

8.  Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome.

Authors:  P Stiefel; A J Vallejo-Vaz; S García Morillo; J Villar
Journal:  Int J Hypertens       Date:  2011-06-23       Impact factor: 2.420

Review 9.  Essential hypertension: an approach to its etiology and neurogenic pathophysiology.

Authors:  Juan J Bolívar
Journal:  Int J Hypertens       Date:  2013-12-09       Impact factor: 2.420

10.  Reversible heart rhythm complexity impairment in patients with primary aldosteronism.

Authors:  Yen-Hung Lin; Vin-Cent Wu; Men-Tzung Lo; Xue-Ming Wu; Chi-Sheng Hung; Kwan-Dun Wu; Chen Lin; Yi-Lwun Ho; Michael Stowasser; Chung-Kang Peng
Journal:  Sci Rep       Date:  2015-08-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.